



SERES
THERAPEUTICS™

Seres Therapeutics to Present at Canaccord Genuity 35th Annual Growth Conference

August 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, today announced that management will present a company overview at the Canaccord Genuity 35th Annual Growth Conference held at the InterContinental Hotel in Boston, Mass. The presentation is scheduled for Thursday, August 13, 2015 at 3:00 p.m. (EDT).

Live audio webcast of the presentation will be available under the Investors and Media section of Seres' website at www.serestherapeutics.com. A replay of the presentation will become available approximately one hour after the event and will be archived on the site for 14 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20150805006526/en/>

Source: Seres Therapeutics, Inc.

IR Contact:

Stern Investor Relations, Inc.
Beth DelGiaccio, 212-362-1200
Beth@sternir.com

or

PR Contact:

Feinstein Kean Healthcare
Liz Melone, 617-256-6622
Liz.melone@fkhealth.com